Results 131 to 140 of about 2,451,718 (370)
Innovations in Opioid Law and Policy Interventions Workshop: Summary of Proceedings [PDF]
, 2018 In 2017, Indiana University, in cooperation with Indiana Governor Eric Holcomb and community partners, launched the Grand Challenge: Responding to the Addictions Crisis initiative, a university-wide effort to advance interdisciplinary research and ...
Beukema, Emily +3 more
core
The newer opioid agonist treatment with lower substitutive opiate doses is associated with better toxicology outcome than the older harm reduction treatment [PDF]
, 2016 Background: Charge-free heroin use disorder treatment in Italy follows two main approaches, i.e., harm reduction treatment (HRT) strategy in community low-threshold facilities for drug addiction and opioid agonist treatment (OAT) in high-threshold ...
Bacciardi, Silvia +8 more
core +1 more source
Clinical Pharmacology in Drug Development, EarlyView.Abstract Long‐acting (LA) cabotegravir 200‐mg/mL (CAB200) injections are approved for HIV‐1 prevention and as a complete LA HIV‐1 treatment regimen with rilpivirine. A high‐concentration suspension formulation, cabotegravir 400 mg/mL (CAB400‐D), was developed to enable less frequent dosing and self‐administration. This phase 1, double‐blind, randomized
Kelong Han +16 more
wiley +1 more source
Towards Better Opioid Antagonists Using Deep Reinforcement Learning [PDF]
arXiv, 2020 Naloxone, an opioid antagonist, has been widely used to save lives from opioid overdose, a leading cause for death in the opioid epidemic. However, naloxone has short brain retention ability, which limits its therapeutic efficacy. Developing better opioid antagonists is critical in combating the opioid epidemic.Instead of exhaustively searching in a ...
arxiv
Health & JusticeBackground The Veterans Health Administration has made strides to improve access to medications for opioid use disorder overall. However, quality improvement methods to assess treatment gaps may not sufficiently detect differences in medication access by
Andrea K. Finlay +7 more
doaj +1 more source
Clinical Pharmacology &Therapeutics, EarlyView.Although attractive for relevance to real‐world scenarios, real‐world data (RWD) is typically used for drug repurposing and not therapeutic target discovery. Repurposing studies have identified few effective options in neurological diseases such as the rare disease, amyotrophic lateral sclerosis (ALS), which has no disease‐modifying treatments ...
Mohammadali Alidoost +9 more
wiley +1 more source
A Big Data Analytics Framework to Predict the Risk of Opioid Use Disorder [PDF]
arXiv, 2019 Overdose related to prescription opioids have reached an epidemic level in the US, creating an unprecedented national crisis. This has been exacerbated partly due to the lack of tools for physicians to help predict the risk of whether a patient will develop opioid use disorder.
arxiv
271 Evaluation of treatment for opioid use disorder across North Carolina: a study protocol
Journal of Clinical and Translational ScienceOBJECTIVES/GOALS: Our objectives are to: 1) characterize opioid treatment providers in North Carolina according to payment methods accepted and ability to provide medications for opioid use disorder and 2) use geomapping technology to characterize ...
Rachel Lynn Graves +3 more
doaj +1 more source
Addiction Science & Clinical Practice, 2020 There is an urgent need for strategies to address the US epidemic of prescription opioid, heroin and fentanyl-related overdoses, misuse, addiction, and diversion.
Gavin B. Bart +7 more
doaj +1 more source
A state-level study of opioid use disorder treatment access and neonatal abstinence syndrome [PDF]
, 2019 Background Adult opioid use and neonatal abstinence syndrome (NAS) are growing public health problems in the United States (U.S.). Our objective was to determine how opioid use disorder treatment access impacts the relationship between adult opioid use ...
Abbinanti, Kassie +6 more
core +1 more source